Copyright
©The Author(s) 2022.
World J Clin Oncol. Jan 24, 2022; 13(1): 49-61
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.49
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.49
Table 2 Cancers observed based on presence or absence of a comorbid inflammatory condition over 10 yr of follow up, n (%)
| Number of patients who developed a cancer | CID present, n = 21 | No CID, n = 43 |
| 12 (57.1) | 20 (46.5) | |
| Lynch syndrome specific cancers | ||
| Colorectal | 9 (42.9) | 12 (27.9) |
| Endometrial | 2 (9.5) | 8 (18.6) |
| Small Bowel | 0 (0) | 1 (2.3) |
| Urothelial | 1 (4.8) | 1 (2.3) |
| Non-Lynch Syndrome-specific cancers | ||
| Breast | 1 (4.8) | 0 (0) |
| Nasopharynx | 1 (4.8) | 0 (0) |
| Prostate | 1 (4.8) | 0 (0) |
| Ovarian | 0 (0) | 1 (2.3) |
| B-Cell Lymphoma | 1 (4.8) | 0 (0) |
- Citation: Faisal MS, Burke CA, Liska D, Lightner AL, Leach B, O’Malley M, LaGuardia L, Click B, Achkar J, Kalady M, Church J, Mankaney G. Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome. World J Clin Oncol 2022; 13(1): 49-61
- URL: https://www.wjgnet.com/2218-4333/full/v13/i1/49.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i1.49